329:
317:
226:
171:
127:
216:
271:
266:
196:
281:
201:
286:
231:
117:
295:
246:
151:
161:
107:
276:
211:
186:
236:
191:
166:
156:
261:
256:
300:
221:
206:
141:
132:
112:
122:
379:
181:
176:
251:
37:
241:
395:
335:
85:
30:
75:
146:
70:
80:
60:
389:
341:
65:
46:
340:
missing, inadequate, or does not accurately describe its functionality or the
311:
19:
323:
15:
227:
Nucleoside and nucleotide reverse-transcriptase inhibitors
372:
364:
360:
347:
172:
Dual serotonin and norepinephrine reuptake inhibitors
98:
53:
357:Editors can experiment in this template's sandbox
217:Non-nucleoside reverse-transcriptase inhibitors
31:
8:
38:
24:
16:
177:Selective serotonin reuptake inhibitors
7:
267:Bcr-Abl tyrosine-kinase inhibitors
14:
282:Neurokinin 1 receptor antagonists
157:Dipeptidyl peptidase-4 inhibitors
327:
315:
272:Cannabinoid receptor antagonists
101:and development of drug classes
1:
118:Angiotensin receptor blockers
296:Melatonin receptor agonists
247:Thalidomide and its analogs
202:Memantine and related drugs
152:Cyclooxygenase 2 inhibitors
412:
356:
162:Direct thrombin inhibitors
99:Case studies of discovery
380:Subpages of this template
277:CCR5 receptor antagonists
348:to expand and improve it
212:Neuraminidase inhibitors
396:Drug navigational boxes
187:HIV-protease inhibitors
108:5α-Reductase inhibitors
320:Template documentation
237:Proton pump inhibitors
192:Integrase inhibitors
167:Direct Xa inhibitors
262:Tubulin inhibitors
354:
353:
309:
308:
257:TRPV1 antagonists
197:Lipase inhibitors
403:
376:
368:
334:This template's
331:
330:
324:
321:
319:
318:
301:Renin inhibitors
147:c-Met inhibitors
71:Drug development
40:
33:
26:
17:
411:
410:
406:
405:
404:
402:
401:
400:
386:
385:
384:
383:
378:
370:
358:
355:
328:
322:
316:
314:
310:
305:
290:
232:PDE5 inhibitors
222:NS5A inhibitors
207:mTOR inhibitors
136:
100:
94:
54:Steps in design
49:
44:
12:
11:
5:
409:
407:
399:
398:
388:
387:
369:and testcases
352:
351:
332:
313:
312:
307:
306:
304:
303:
298:
293:
288:
284:
279:
274:
269:
264:
259:
254:
249:
244:
239:
234:
229:
224:
219:
214:
209:
204:
199:
194:
189:
184:
179:
174:
169:
164:
159:
154:
149:
144:
142:Cephalosporins
139:
134:
130:
125:
120:
115:
113:ACE inhibitors
110:
104:
102:
96:
95:
93:
92:
91:
90:
89:
88:
78:
68:
63:
61:Drug discovery
57:
55:
51:
50:
45:
43:
42:
35:
28:
20:
13:
10:
9:
6:
4:
3:
2:
408:
397:
394:
393:
391:
381:
374:
366:
362:
349:
345:
343:
337:
336:documentation
333:
326:
325:
302:
299:
297:
294:
292:
285:
283:
280:
278:
275:
273:
270:
268:
265:
263:
260:
258:
255:
253:
250:
248:
245:
243:
240:
238:
235:
233:
230:
228:
225:
223:
220:
218:
215:
213:
210:
208:
205:
203:
200:
198:
195:
193:
190:
188:
185:
183:
180:
178:
175:
173:
170:
168:
165:
163:
160:
158:
155:
153:
150:
148:
145:
143:
140:
138:
131:
129:
128:Beta-blockers
126:
124:
123:Antiandrogens
121:
119:
116:
114:
111:
109:
106:
105:
103:
97:
87:
84:
83:
82:
79:
77:
74:
73:
72:
69:
67:
64:
62:
59:
58:
56:
52:
48:
41:
36:
34:
29:
27:
22:
21:
18:
346:Please help
344:in its code.
339:
23:
291:antagonists
76:Preclinical
66:Hit to lead
47:Drug design
342:parameters
182:Gliflozins
390:Category
252:Triptans
137:agonists
81:Clinical
363:|
242:Statins
377:pages.
373:create
365:mirror
361:create
86:Phases
287:5-HT
133:Beta
338:is
392::
382:.
375:)
371:(
367:)
359:(
350:.
289:3
135:2
39:e
32:t
25:v
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.